ASX-listed biotech Opthea says it has terminated the second of its two trials of drugs to treat a common eye disease, delivering a near mortal blow to shareholders who had already written down the majority of their investments.
The company said on Monday that a second phase 3 trial “did not meet its primary endpoint” after disappointing investors only last week with the news that a first phase 3 trial had failed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。